IPM December 2025: Pharma Giants Soar, Mounjaro Leads Diabetes Revolution

• Indian Pharmaceutical Market (IPM) grew 10.6% in December 2025, with major players showing double-digit growth.
• Torrent Pharma (17.2%), Cipla (15.5%), Sun Pharma (15.2%), Lupin (12.8%), Zydus (12.7%), and Dr Reddy’s (10.1%) led the growth.
• The anti-diabetic segment, valued at ₹22,280 crore, grew 9.4% MAT, becoming a fastest-growing chronic therapy area.
• Eli Lilly's Mounjaro ranked #1 in December, becoming the fastest brand to top monthly sales since October 2025 despite premium pricing.
• New-age therapies like Mounjaro are shifting market leadership, signaling rapid evolution in India's pharma market, especially in diabetes care.

Why It Matters: India's pharma market sees strong growth, with new therapies like Mounjaro driving significant shifts in leadership.